AZRX vs. OKUR, COCP, NNVC, GLYC, MRKR, MEIP, QNTM, AFMD, SLGL, and SPRB
Should you be buying AzurRx BioPharma stock or one of its competitors? The main competitors of AzurRx BioPharma include OnKure Therapeutics (OKUR), Cocrystal Pharma (COCP), NanoViricides (NNVC), GlycoMimetics (GLYC), Marker Therapeutics (MRKR), MEI Pharma (MEIP), Quantum Biopharma (QNTM), Affimed (AFMD), Sol-Gel Technologies (SLGL), and Spruce Biosciences (SPRB). These companies are all part of the "medical" sector.
AzurRx BioPharma vs.
AzurRx BioPharma (NASDAQ:AZRX) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.
6.3% of AzurRx BioPharma shares are owned by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are owned by institutional investors. 7.3% of AzurRx BioPharma shares are owned by company insiders. Comparatively, 17.9% of OnKure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
OnKure Therapeutics is trading at a lower price-to-earnings ratio than AzurRx BioPharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, AzurRx BioPharma's average media sentiment score of 0.00 equaled OnKure Therapeutics'average media sentiment score.
AzurRx BioPharma received 220 more outperform votes than OnKure Therapeutics when rated by MarketBeat users. However, 100.00% of users gave OnKure Therapeutics an outperform vote while only 74.26% of users gave AzurRx BioPharma an outperform vote.
AzurRx BioPharma has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500. Comparatively, OnKure Therapeutics has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500.
OnKure Therapeutics has a consensus price target of $36.00, indicating a potential upside of 559.34%. Given OnKure Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe OnKure Therapeutics is more favorable than AzurRx BioPharma.
OnKure Therapeutics' return on equity of -51.17% beat AzurRx BioPharma's return on equity.
Summary
OnKure Therapeutics beats AzurRx BioPharma on 9 of the 14 factors compared between the two stocks.
Get AzurRx BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for AZRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AzurRx BioPharma Competitors List
Related Companies and Tools
This page (NASDAQ:AZRX) was last updated on 2/23/2025 by MarketBeat.com Staff
